Posted inBiotechnology
Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial
A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing…









